Search research articles
Contact Us
Filters
Showing results (61-70 of 82) with videos related to
Page
of 9
Sort By:
Journal of Neurology
|
April 7, 2026
Cerebrospinal fluid alpha-internexin concentrations measured in patients with Guillain-Barré syndrome: a possible prognostic biomarker for disability at 12 months
Nina Gleisner, Francisco Meda, Magnus Johnsson, et al.
Journal of the Neurological Sciences
|
July 7, 2024
High levels of neurofilament light and YKL-40 in cerebrospinal fluid are related to poor outcome in ALS
Christoffer Rosén, Bernardo Mitre, Bengt Nellgård, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)
|
October 17, 2012
Cerebrospinal fluid biomarkers of β-amyloid metabolism in multiple sclerosis
Kristin Augutis, Markus Axelsson, Erik Portelius, et al.
European Journal of Neurology
|
April 16, 2025
Brain-Derived Tau as an Outcome Marker in Guillain-Barré Syndrome: A Retrospective Cohort Study
Brynhildur Hafsteinsdóttir, Fernando Gonzalez-Ortiz, Nina Gleisner, et al.
Annals of Neurology
|
February 1, 2011
Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab
Martin Gunnarsson, Clas Malmeström, Markus Axelsson, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
May 28, 2020
Inflammation-related plasma and CSF biomarkers for multiple sclerosis
Jesse Huang, Mohsen Khademi, Lars Fugger, et al.
Journal of Neurology
|
September 9, 2024
Neurofilament light chain as a diagnostic and prognostic biomarker in Guillain-Barré syndrome
Brynhildur Hafsteinsdóttir, Helen Farman, Nina Lagerström, et al.
Neurology
|
October 29, 2017
Monitoring disease activity in multiple sclerosis using serum neurofilament light protein
Lenka Novakova, Henrik Zetterberg, Peter Sundström, et al.
Journal of Neurochemistry
|
April 21, 2018
Sulfatide isoform pattern in cerebrospinal fluid discriminates progressive MS from relapsing-remitting MS
Lenka Novakova, Avadhesh Kumar Singh, Markus Axelsson, et al.
Annals of Neurology
|
April 3, 2016
Rituximab versus fingolimod after natalizumab in multiple sclerosis patients
Peter Alping, Thomas Frisell, Lenka Novakova, et al.
Page
of 9
Search research articles
Search
Showing results (61-70 of 82) with videos related to
Sort By:
Page
of 9
Journal of Neurology
|
April 7, 2026
Cerebrospinal fluid alpha-internexin concentrations measured in patients with Guillain-Barré syndrome: a possible prognostic biomarker for disability at 12 months
Nina Gleisner, Francisco Meda, Magnus Johnsson, et al.
Journal of the Neurological Sciences
|
July 7, 2024
High levels of neurofilament light and YKL-40 in cerebrospinal fluid are related to poor outcome in ALS
Christoffer Rosén, Bernardo Mitre, Bengt Nellgård, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)
|
October 17, 2012
Cerebrospinal fluid biomarkers of β-amyloid metabolism in multiple sclerosis
Kristin Augutis, Markus Axelsson, Erik Portelius, et al.
European Journal of Neurology
|
April 16, 2025
Brain-Derived Tau as an Outcome Marker in Guillain-Barré Syndrome: A Retrospective Cohort Study
Brynhildur Hafsteinsdóttir, Fernando Gonzalez-Ortiz, Nina Gleisner, et al.
Annals of Neurology
|
February 1, 2011
Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab
Martin Gunnarsson, Clas Malmeström, Markus Axelsson, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
May 28, 2020
Inflammation-related plasma and CSF biomarkers for multiple sclerosis
Jesse Huang, Mohsen Khademi, Lars Fugger, et al.
Journal of Neurology
|
September 9, 2024
Neurofilament light chain as a diagnostic and prognostic biomarker in Guillain-Barré syndrome
Brynhildur Hafsteinsdóttir, Helen Farman, Nina Lagerström, et al.
Neurology
|
October 29, 2017
Monitoring disease activity in multiple sclerosis using serum neurofilament light protein
Lenka Novakova, Henrik Zetterberg, Peter Sundström, et al.
Journal of Neurochemistry
|
April 21, 2018
Sulfatide isoform pattern in cerebrospinal fluid discriminates progressive MS from relapsing-remitting MS
Lenka Novakova, Avadhesh Kumar Singh, Markus Axelsson, et al.
Annals of Neurology
|
April 3, 2016
Rituximab versus fingolimod after natalizumab in multiple sclerosis patients
Peter Alping, Thomas Frisell, Lenka Novakova, et al.
Page
of 9